Pfizer has suspended patient enrollment in its late-stage lung cancer study of figitumumab, also known as CP-751871, due to serious adverse events, including deaths – reported Trading Markets.
Czura Thornton has signed an agreement to acquire the global central laboratory (GCL) operations of MDS Pharma Services, a business unit of MDS Pharma Services. Reportedly, GCL provides
BASF SE (Deutsche Börse: BAS) and The Dow Chemical Company, have jointly come forward to support the Patent Asset Index (PAI), a new methodology that measures research and
BioAlliance Pharma (BioAlliance) has got the approval from the French Drug Agency (AFSSaPS) to enter first phase I clinical trial for Fentanyl Lauriad. Reportedly, the clinical trial will
Sun Pharmaceutical Industries has got the US FDA approval to launch a generic version of Sanofi-Aventis’ cancer drug Eloxatin and sumatriptan succinate tablets, the generic version of GlaxoSmithKline’s
Arch Pharmalabs (Arch) has entered into a strategic partnership with Orochem Technologies (Orochem) to manufacture a US innovator’s active pharmaceutical ingredient (API) in late-stage clinical development, using Simulated
Santarus and Norgine have entered into a licensing agreement granting exclusive rights to Norgine to develop, manufacture and commercialise prescription immediate-release Zegerid products. It incorporates the proton pump
Heptares Therapeutics (Heptares) has entered into an option agreement with the Novartis Option Fund. As per the deal, Heptares will apply its proprietary StaR technology to generate novel
Onyx Pharmaceuticals (Onyx) has signed an agreement to acquire Proteolix, a biopharmaceutical company focused on novel therapies that target the proteasome for the treatment of hematological malignancies and
Merial Animal Health (Merial), the Animal Health division of Sanofi-Aventis, has started the expansion project at its poultry vaccines plant located in the Nanchang Hi-tech Development Zone, China.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.